Navamedic announces additional patent granted for recently-acquired digital urine measurement system Sippi
Navamedic today announced that the Swedish Patent and Registration Office has granted a patent pertaining to Sippcoat, Observe Medicals innovative encapsulated silicone-oil technology for biofilm inhibition.
- We are pleased with the positive news from the Swedish Patent and Registration Office, which points the way forward and will further strengthen the intellectual property protection for our unique and innovative biofilm inhibition technology, says Tom Rönnlund, CEO of Navamedic. The approval of this patent is an important addition to the family of patents protecting the Sippi system.
The announcement from the Swedish Patent and Registration office relates to a patent entitled " Improved Urine Measurement Device and Method ". It covers a significant part of the strategy that Sippi, the recently-launched digital urine measurement system, utilizes for its non-toxic and environmentally sustainable method for reducing biofilm formation within a urine-measurement device.
Biofilm formation has a causal link with nearly all hospital-acquired infections, and reducing the bacterial colonization of the surface of medical materials, via prevention of biofilm build-up in a simple and sustainable way, is of great importance and value to hospitals and patients across the world. For example, urinary tract infection (UTI) represents 40% of all hospital-acquired infections, and inhibiting biofilm growth in urine measurement devices could substantially improve this situation.
"-This is an important milestone for the Sippi system and we expect to initiate additional studies on the practical and clinical effects of Sippcoat to add to the growing body of evidence supporting the benefits of Sippi in ICU's", says Magnus Emmoth, Head of Medtech at Navamedic.
The product system Sippi was acquired by Navamedic ASA in August 2015 and is currently being launched in the German and Nordic markets. The acquisition of the innovative product is a part of Navamedics strategy to increase the proportion of own products in its portfolio.
For further information, please contact CEO Tom Rönnlund, telephone +46 727 320 321 or CFO Bjørn Lindholt, telephone +47 9300 6601.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.